NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free BLUE Stock Alerts $0.99 +0.02 (+1.74%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$0.97▼$1.0250-Day Range$0.95▼$1.7552-Week Range$0.88▼$5.53Volume217,097 shsAverage Volume8.73 million shsMarket Capitalization$107.97 millionP/E RatioN/ADividend YieldN/APrice Target$5.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside504.8% Upside$5.87 Price TargetShort InterestHealthy27.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 10 Articles This WeekInsider TradingSelling Shares$4,134 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.78) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.81 out of 5 starsMedical Sector397th out of 909 stocksBiological Products, Except Diagnostic Industry59th out of 156 stocks 3.2 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted27.21% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bluebird bio has recently decreased by 12.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 1.7 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for bluebird bio this week, compared to 5 articles on an average week.Search InterestOnly 41 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 19 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,134.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($1.78) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesApril 23, 2024 | money.usnews.comBluebird bio IncApril 23, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmApril 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 22, 2024 | prnewswire.comLost Money on bluebird bio, Inc.(BLUE)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyApril 21, 2024 | markets.businessinsider.comROSEN, National Trial Lawyers, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUEApril 19, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmApril 19, 2024 | prnewswire.combluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUEApril 24, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. April 18, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitApril 17, 2024 | msn.combluebird bio (BLUE) Price Target Decreased by 7.15% to 4.24April 17, 2024 | prnewswire.comROSEN, NATIONAL TRIAL LAWYERS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUEApril 16, 2024 | prnewswire.comClass Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law FirmApril 16, 2024 | msn.comTD Cowen says sickle cell therapies may get higher CMS paymentsApril 16, 2024 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Recommendation of "Hold" from AnalystsApril 15, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitApril 15, 2024 | fool.comIs Bluebird Bio Stock a Buy?April 15, 2024 | prnewswire.combluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEApril 14, 2024 | stockhouse.comROSEN, LEADING TRIAL ATTORNEYS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUEApril 14, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BlueApril 13, 2024 | markets.businessinsider.comROSEN, A Leading Law Firm, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 13, 2024 | fool.comBetter Buy: Bluebird Bio Vs. NovavaxApril 12, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 12, 2024 | businesswire.comFederman & Sherwood Announces Filing of Securities Class Action Lawsuit Against BlueBird Bio, Inc. (NASDAQ: BLUE)April 12, 2024 | businesswire.comBLUE Shareholders with Significant Losses are Urged to Contact Robbins LLP to Discuss the bluebird bio, Inc. Class ActionApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUEApril 12, 2024 | prnewswire.comShareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$5.87 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+504.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-419.64% Pretax Margin-419.50% Return on Equity-34.32% Return on Assets-14.44% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.42 Sales & Book Value Annual Sales$3.60 million Price / Sales29.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.41Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$106.13 million OptionableOptionable Beta0.74 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsOutlook TherapeuticsNASDAQ:OTLKBioAtlaNASDAQ:BCABaTyr PharmaNASDAQ:LIFEVigil NeuroscienceNASDAQ:VIGLSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsEnterprise Bank & Trust CoBought 30,000 shares on 4/10/2024Ownership: 0.027%HBK Investments L PBought 1,500,000 shares on 3/14/2024Ownership: 1.372%Virtu Financial LLCBought 229,542 shares on 2/26/2024Ownership: 0.210%PFM Health Sciences LPSold 3,998,283 shares on 2/15/2024Ownership: 1.868%Birchview Capital LPSold 134,000 shares on 2/15/2024Ownership: 0.294%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price target for 2024? 12 Wall Street analysts have issued 1 year price objectives for bluebird bio's shares. Their BLUE share price targets range from $1.02 to $13.00. On average, they anticipate the company's share price to reach $5.87 in the next twelve months. This suggests a possible upside of 504.8% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2024? bluebird bio's stock was trading at $1.38 on January 1st, 2024. Since then, BLUE shares have decreased by 29.7% and is now trading at $0.9706. View the best growth stocks for 2024 here. Are investors shorting bluebird bio? bluebird bio saw a drop in short interest in March. As of March 31st, there was short interest totaling 29,750,000 shares, a drop of 12.6% from the March 15th total of 34,040,000 shares. Based on an average daily volume of 9,070,000 shares, the short-interest ratio is currently 3.3 days. View bluebird bio's Short Interest. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.03. The biotechnology company earned $12.40 million during the quarter, compared to the consensus estimate of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The company's quarterly revenue was up 17364.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.92) earnings per share. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM). What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Enterprise Bank & Trust Co (0.03%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLUE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingElon Musk’s Controversial New Project: “Apollo”InvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
